BRPI0923300A2 - "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas" - Google Patents

"derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"

Info

Publication number
BRPI0923300A2
BRPI0923300A2 BRPI0923300A BRPI0923300A BRPI0923300A2 BR PI0923300 A2 BRPI0923300 A2 BR PI0923300A2 BR PI0923300 A BRPI0923300 A BR PI0923300A BR PI0923300 A BRPI0923300 A BR PI0923300A BR PI0923300 A2 BRPI0923300 A2 BR PI0923300A2
Authority
BR
Brazil
Prior art keywords
cilostazol
vascular
treatment
metabolic diseases
nitrate derivatives
Prior art date
Application number
BRPI0923300A
Other languages
English (en)
Inventor
Scherhag Armin
Sartor Dirk
Original Assignee
Cardiolynx Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiolynx Ag filed Critical Cardiolynx Ag
Publication of BRPI0923300A2 publication Critical patent/BRPI0923300A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas a presente invenção refere-se a derivados de nitrato de cilostazol. eles têm propriedades superiores e vantagens clínicas quando comparados com o cilostazol para o tratamento de doenças vasculares e metabólicas.
BRPI0923300A 2008-12-02 2009-12-01 "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas" BRPI0923300A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170435A EP2194048A1 (en) 2008-12-02 2008-12-02 Nitrate esters for the treatment of vascular and metabolic diseases
PCT/EP2009/066159 WO2010063724A1 (en) 2008-12-02 2009-12-01 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Publications (1)

Publication Number Publication Date
BRPI0923300A2 true BRPI0923300A2 (pt) 2019-07-16

Family

ID=40456966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923300A BRPI0923300A2 (pt) 2008-12-02 2009-12-01 "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"

Country Status (14)

Country Link
US (1) US8426597B2 (pt)
EP (2) EP2194048A1 (pt)
JP (1) JP2012510502A (pt)
KR (1) KR20110088598A (pt)
CN (1) CN102245583A (pt)
AU (1) AU2009324123A1 (pt)
BR (1) BRPI0923300A2 (pt)
CA (1) CA2745252A1 (pt)
IL (1) IL213214A0 (pt)
MX (1) MX2011005744A (pt)
RU (1) RU2011126607A (pt)
SG (1) SG171423A1 (pt)
WO (1) WO2010063724A1 (pt)
ZA (1) ZA201104011B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
TW201204355A (en) 2010-06-02 2012-02-01 Cardiolynx Ag Nitrate derivatives of pioglitazone
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
EP2887952B1 (en) 2012-08-21 2019-05-15 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
EP3321254B1 (en) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
TR201911272T4 (tr) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Paliperidon haptenleri.
JP6171014B2 (ja) 2012-08-21 2017-07-26 ヤンセン ファーマシューティカ エヌ．ベー． オランザピン（Ｏｌａｎｚｉｐｉｎｅ）のハプテン
CN104736536B (zh) 2012-08-21 2018-09-25 詹森药业有限公司 用于免疫测定的喹硫平半抗原
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888592T3 (pl) 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
CA2882560C (en) 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of risperidone and paliperidone for use in immunoassays
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN114044766B (zh) * 2021-10-09 2022-12-27 张北北九食品检验技术有限公司 放射性同位素碳-14标记的呋虫胺和中间体及其制备方法和应用
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US6148496A (en) 1999-04-09 2000-11-21 The Procter & Gamble Company Method for making a seamless apertured metal belt
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
RU2374240C2 (ru) 2003-07-31 2009-11-27 Никокс С.А. Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Also Published As

Publication number Publication date
MX2011005744A (es) 2011-06-20
JP2012510502A (ja) 2012-05-10
SG171423A1 (en) 2011-07-28
CA2745252A1 (en) 2010-06-10
EP2194048A1 (en) 2010-06-09
CN102245583A (zh) 2011-11-16
US8426597B2 (en) 2013-04-23
KR20110088598A (ko) 2011-08-03
US20110230520A1 (en) 2011-09-22
RU2011126607A (ru) 2013-01-10
EP2367803A1 (en) 2011-09-28
IL213214A0 (en) 2011-07-31
ZA201104011B (en) 2012-02-29
AU2009324123A1 (en) 2011-07-21
WO2010063724A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
MX2012002179A (es) Compuestos heterociclicos de oxima.
JO3265B1 (ar) مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
NZ595189A (en) Combination therapy with thiocolchicine derivatives
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX339302B (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
MX340577B (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
IN2012DN00953A (pt)
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX2010009837A (es) Tiazolil-dihidro-indazoles.
BR112014032169A2 (pt) tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
ATE474574T1 (de) Imidazoazephinonverbindungen

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE REIVINDICADA EP 08170435.5 DE 02.12.2008 POIS NAO FOI RESPONDIDA A EXIGENCIA FORMULADA NA RPI 2518 DE 09/04/2019 SOBRE ESTA PRIORIDADE.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]